Page 2 - இணைப்பு திசு புற்றுநோயியல் சமூகம் News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Stay updated with breaking news from இணைப்பு திசு புற்றுநோயியல் சமூகம். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.

Top News In இணைப்பு திசு புற்றுநோயியல் சமூகம் Today - Breaking & Trending Today

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines

Antengene Announces Selinexor Added to Multiple Treatment Regimens in 2021 CSCO Guidelines
News provided by
Share this article
Share this article
SHANGHAI and HONG KONG, May 5, 2021 /PRNewswire/ Antengene Corporation Limited ( Antengene , SEHK: 6996.HK), a leading innovative biopharmaceutical company dedicated to discovering, developing and commercializing global first-in-class and/or best-in-class therapeutics in hematology and oncology, today announced that the Chinese Society of Clinical Oncology (CSCO), the most prominent organization in oncology in China,
added multiple selinexor regimens to its 2021 Diagnosis and Treatment Guidelines (CSCO Guidelines) for treatment of multiple myeloma and lymphoma. Three selinexor regimens recommended by the Guideline for the Diagnosis and Treatment of myeloma include: (i) selinexor plus dexamethasone; and (ii) selinexor plus dexamethasone plus bortezomib; and (iii) selinexor plus dexamethasone plus pomalidomide for t ....

Kyongsang Bukto , South Korea , New Zealand , Hong Kong , Wenming Chen , Asia Pacific , Depei Wu , Chao Yang Hospital Of The Capital Medical University , Karyopharm Therapeutics Inc , Antengene Corporation , European Commission , Drug Administration , Chinese Medical Education Association Committee On Hematology , Antengene Corporation Limited , Connective Tissue Oncology Society , Ministry Of Food , First Affiliated Hospital Of Soochow University , Israeli Ministry Of Health , National Comprehensive Cancer Network , Chinese Society , Chinese Medical Association , First Affiliated Hospital , Soochow University , Chinese Medical Education Association Committee , Beijing Chaoyang Hospital , Capital Medical University ,

Andrzej Kudelka MD, FACP, FACE is recognized by Continental Who's Who

Andrzej Kudelka MD, FACP, FACE is recognized by Continental Who's Who
prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.

United States , Hilo Medical Center , Andrzej Kudelka , Phi Beta Kappa , Department Of Clinical Investigation , Courant Institute Of Mathematical Sciences , Department Of Breast Medical Oncology , American Society Of Clinical Oncology , University Of New York At Stony Brook , Therapeutics Committee , Department Of Gynecologic Medical Oncology , Society For Melanoma Research , Connective Tissue Oncology Society , Patient Safety Committee At Stony Brook University , Society Of Gynecologic Oncology , Department Of Medicine , American Academy Of Hospice , American College Of Endocrinology , Stony Brook Cancer Center Pharmacy , Department Of Clinical Immunology , City College , Columbia University , American College Of Physicians , Department Of Medical Oncology , American Association Of Clinical Endocrinologists , American Association For Cancer Research ,

Oncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call Transcript

Oncternal Therapeutics, Inc. (ONCT) Q4 2020 Earnings Call Transcript
msn.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from msn.com Daily Mail and Mail on Sunday newspapers.

United States , San Diego , Kumar Raja , Carl Byrnes , James Breitmeyer , Shivendu Seneroy , Edwina Baskin Bey , Jim Breitmeyer , Richard Vincent , Carl Byrnes Northland , Velosbio Inc , California Institute For Regenerative Medicine , Karolinska Institute , Drug Administration , Boehringer Ingelheim , Merck Co , American Society Of Hematology , Lentigen Technology , Oncternal Therapeutics Inc , Motley Fool Oncternal Therapeutics Inc , Connective Tissue Oncology Society , Uc San Diego School Of Medicine , Oncternal Therapeutics , Motley Fool Oncternal Therapeutics , Call Transcript , Motley Fool Logo ,

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results

Cogent Biosciences Reports Fourth Quarter 2020 and Full Year 2020 Financial Results
CGT9486 clinical trial initiations on-track: Advanced Systemic Mastocytosis (1H21), Non-Advanced Systemic Mastocytosis (2H21), Gastrointestinal Stromal Tumors (GIST) (2H21)
Final data from CGT9486 + sunitinib Phase 1/2 study presented at CTOS 2020 demonstrated 12 months median PFS and 20% ORR, including a complete response, in heavily pre-treated advanced GIST patients. Randomized GIST clinical trial initiation expected in 2H21
Rapidly Growing with Several Key Additions to Management Team and Board of Directors
Ended Q4 2020 with $242.2 million in cash, funding operations into 2024
News provided by
Share this article
Share this article
CAMBRIDGE, Mass., March 16, 2021 /PRNewswire/ Cogent Biosciences, Inc. (Nasdaq: COGT), a biotechnology company focused on developing precision therapies for genetically defined diseases, today announced financial results for the fo ....

United Kingdom , Andrew Robbins , Todde Shegog , Cogent Biosciences Inc , Kent State University , Lafayette College , Regulatory Affairs , Regulatory Affairs For Unum Therapeutics , Program Management For Oncology , Northeastern University , Colby College , Connective Tissue Oncology Society , Program Team Leader , University Of Colorado Denver , Cogent Biosciences , Public Offering , Chief Financial Officer , Forma Therapeutics , Cogent Bioscience , Tepper School , Carnegie Mellon , Senior Vice President , Vice President , Global Head , Risk Management , Array Biopharma ,

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress

Karyopharm Reports Fourth Quarter and Full Year 2020 Financial Results and Highlights Recent Company Progress
Commercial Launch of XPOVIO® (selinexor) In Expanded Multiple Myeloma Indication Fully Underway Following December 18, 2020 FDA Approval
XPOVIO Net Product Sales of $20.2 Million for Fourth Quarter 2020 and $76.2 Million for the Year 2020; Total Revenues of $35.1 Million for the Fourth Quarter 2020 and $108.1 Million for the Year 2020
Positive CHMP Opinion for NEXPOVIO® (selinexor) in Penta-Refractory Multiple Myeloma Issued; European Commission Decision Expected by April 2021
Conference Call Scheduled for Today at 8:30 a.m. ET
News provided by
Share this article
Share this article ....

United States , Michaelg Kauffman , Chen Schor , Selective Inhibitor Of Nuclear Export , Adicet Bio Inc , American Society Of Hematology , Therapeutics Inc , European Union , Karyopharm Selective Inhibitor Of Nuclear Export , Connective Tissue Oncology Society , Committee For Medicinal Products Human Use , National Comprehensive Cancer Network , Information Department , Karyopharm Therapeutics Inc , Drug Administration , European Commission , Progress Towards The International Expansion , Exchange Commission , Prnewswire Karyopharm Therapeutics Inc , Development For Solid Tumors , European Medicines Agency , Antengene Therapeutics , Israeli Ministry Of Health , Chief Executive Officer , Clinical Practice Guidelines , Medicinal Products ,